Traded Jul 2, 2026 · Filed Jul 7, 2026
A board member of Regeneron Pharmaceuticals sold $130K of Regeneron Pharmaceuticals shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$130,030
Shares × reported transaction price
64 days after results of Apr 29, 2026, 4 days before results of Jul 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $654.27 on Jul 2, 2026, 22% above its 52-week low and 19% below its high, after a 4% rise over the previous 30 trading days
52-week range $538.11 (Jul 7, 2025) to $812.27 (Jan 7, 2026), 42% of the way up, from 251 adjusted closes. 30 trading days earlier: $630.30 on May 19, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Jan 7, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
In re Regeneron Pharmaceuticals, Inc. Securities Litigation, docket 1:25-cv-00145, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.2% | +1.3% | -1.0% |
| 30 days | +18.3% | +3.7% | +14.6% |
Past results only. Not a forecast.
3 different filers disclosed REGN within 90 days. Disclosed 116 days after the transaction; reported as an official range, not an exact amount.
2 different filers disclosed REGN within 90 days. Disclosed 24 days after the transaction; reported as an official range, not an exact amount.
Director sold ~$3.5K of Regeneron Pharmaceuticals
Scheduled in advance
Congress trade